In Vitro Screening CROs

Leading global pharmaceutical and medical device open-access capability and technology platform. WuXi AppTec provides services spanning from discovery through manufacturing across small molecules, biologics, and cell/gene therapies.

Global leader in providing preclinical and clinical laboratory services. Charles River offers early-stage discovery, safety assessment, and clinical support services to pharmaceutical and biotech companies worldwide.

Specialty ADME/PK CRO providing in vitro and in vivo drug metabolism and pharmacokinetic studies. Known for comprehensive ADME characterization using human and animal tissues.

Preclinical ADME and pharmacokinetic service provider now part of Pharmaron. Specializes in in vitro and in vivo DMPK, drug transporter studies, and metabolite identification.

San Diego-based preclinical CRO providing in vitro ADME screening, permeability assays, and metabolic stability studies for drug discovery programmes.

Chinese integrated drug discovery and development CRO providing medicinal chemistry, ADME/PK, pharmacology, toxicology, and CMC services from Shanghai operations.

Integrated pharmaceutical R&D service platform offering drug discovery, preclinical, clinical, and commercial manufacturing services to biotech and pharma companies globally.

Drug discovery and development company offering a range of discovery and preclinical services including target validation, hit identification, lead optimization, and ADME/PK.

Specialty CRO providing biochemical and cell-based assay services for drug discovery. Known for kinase profiling, epigenetic screening, and custom assay development.

Translational oncology and metabolic disease CRO providing tumor models (PDX, syngeneic, humanized), oncology pharmacology, and biomarker services for drug discovery.

Fully integrated German CRO/CDMO offering drug discovery, non-clinical studies, pharmaceutical analysis, GMP manufacturing, and early-phase clinical trials from facilities in Germany and France.

World-leading ophthalmology-specialized CRO conducting preclinical and clinical research from ocular surface to posterior segment, with 70+ ocular drugs and devices brought to market.

North Carolina-based genetic toxicology CRO providing GLP-compliant Ames, micronucleus, chromosomal aberration, and comet assays for regulatory submissions.

Eurofins Discovery division providing high-throughput in-vitro pharmacology screening, compound profiling, ADME assays, and bioanalytical services supporting drug discovery from target identification through lead optimization.

French preclinical CRO based in Lyon evaluating efficacy and safety of new compounds including drugs, biologics, and medical devices across innovative in-vitro and in-vivo models.

Nonprofit research organization providing drug discovery, preclinical development, and analytical services with deep expertise in oncology and infectious disease including BSL-3 capabilities.

Preclinical ADME and pharmacokinetics CRO in Pennsylvania providing in vitro and in vivo absorption, distribution, metabolism, and excretion studies as part of Pharmaron's global network.

Drug discovery services company providing in vitro pharmacology screening, ADME profiling, and custom assay development for pharmaceutical and biotech companies.

Global CRO/CDMO providing integrated drug discovery and development services including medicinal chemistry, ADME/PK, pharmacology, and process chemistry from US and China operations.

Chinese CRO/CDMO providing integrated drug discovery services including structure-based drug design, medicinal chemistry, ADME/PK studies, and biologics development from Shanghai operations.

Indian integrated research, development, and manufacturing services company serving pharma, biotech, and nutrition companies with discovery chemistry, biology, and manufacturing capabilities.

Indian research services company providing medicinal chemistry, computational chemistry, biology, DMPK, and clinical development services for global pharma and biotech companies.

Integrated drug discovery and development services company providing medicinal chemistry, ADME/DMPK, pharmacology, and clinical research from India, US, and China operations.

Preclinical oncology CRO using patient-derived tumor models and TumorGraft technology for in vivo efficacy studies, providing translational research services for oncology drug development.

Japanese preclinical ADME services company providing in vitro metabolism, transporter, and drug interaction studies using human and animal tissue preparations for drug development.

Hyderabad-headquartered integrated CRDMO providing CRO and CDMO solutions for small and large molecules to 450+ global pharma and biotech clients with 3,000+ professionals.

Shanghai-headquartered CRO/CDMO offering integrated drug discovery chemistry, biology, and biologics development services including ADC and recombinant protein production.

Germany-based mid-size CRO providing early-phase clinical trials (Phase I/IIa), bioanalysis, DMPK, and translational medicine services from facilities in Neu-Ulm and Berlin.

Oncology-focused CRO founded on the Mayo Clinic campus offering preclinical-to-clinical oncology development with PDX models, flow cytometry, and Phase I/II trial management.

Specialty preclinical CRO offering bioanalytical chemistry, in vitro ADME screening, physicochemical profiling, and metabolite identification for drug discovery programs.

German preclinical oncology CRO providing patient-derived xenograft models, ex vivo tumor assays, and in vivo efficacy studies for oncology drug development programs.

European CRO providing preclinical contract research services including in vivo pharmacology, toxicology, and bioanalytical testing from GLP-certified European facilities.

European ADME and DMPK specialist CRO providing in vitro ADME screening, drug-drug interaction studies, and physicochemical profiling from Macclesfield and Watertown facilities.

Croatian integrated drug discovery CRO providing medicinal chemistry, biology, DMPK, and preclinical development services, now part of Polish CRO Selvita Group.

Hyderabad-headquartered pharmaceutical CRO with dedicated clinical trials division providing drug discovery, early-phase clinical, and regulatory support with strong CNS expertise.

Contract research organization providing discovery, preclinical, and development chemistry services including API synthesis, safety pharmacology, and medicinal chemistry.

Polish integrated drug discovery CRO providing medicinal chemistry, biology, DMPK, computational chemistry, and preclinical services with 1,000+ scientists across Europe.

Kobe-based Japanese CRO and research institute specializing in preclinical safety assessment, pharmacology and drug metabolism studies with GLP-accredited facilities.

Kansas City-based in vitro ADME and drug metabolism CRO providing hepatocyte-based assays, enzyme induction/inhibition studies, and metabolite identification services.

Hanover, Maryland-based drug screening CRO offering high-throughput receptor binding, enzyme inhibition, and functional cell-based assays for hit-to-lead optimisation programmes.

Verona, Italy-based integrated drug discovery and development centre providing medicinal chemistry, DMPK, safety assessment, and pharmaceutical development under the Evotec umbrella.

Global precision medicine CRO delivering biomarker and bioanalytical services including flow cytometry, histopathology, proteomics, and genomics for clinical trials.

Full-continuum preclinical CRO providing integrated in vitro and in vivo services including efficacy, toxicity, biodistribution, and product release studies in small and large animals.

Preclinical CRO specialising in immunotoxicology and immune safety assessment, offering in vivo and in vitro studies for pharma, biotech, and government clients.

AI-enabled precision oncology CRO using patient-derived xenograft models and ex vivo pharmacology to generate predictive therapeutic response data for drug developers.

Indian CRO affiliated with Dabur offering preclinical drug discovery, IND-enabling studies, and non-clinical research services from facilities near Delhi.

One of China's earliest chemistry-focused CROs offering integrated drug discovery, DMPK, and pharmaceutical development services globally.

Chinese CRO and CDMO offering integrated preclinical biology, in-vitro pharmacology, and early drug discovery services for domestic and multinational pharma clients.

Kentucky-based preclinical CRO specialising in oncology efficacy studies using proprietary humanised rodent models and patient-derived xenografts for immuno-oncology drug development.

Italy-based CRO specialising in cardiovascular safety pharmacology and cardiac ion channel testing with proprietary automated patch-clamp platforms.

Zagreb-based drug discovery CRO (Selvita Group) providing integrated medicinal chemistry, ADME/PK, and in vitro biology services for hit-to-lead and lead optimization programs.

New Jersey-based dermatology and personal care CRO conducting clinical trials, product testing, and consumer perception studies for pharmaceutical, cosmetic, and OTC skincare products.

Israeli biotech CRO specializing in preclinical efficacy models for wound healing, dermatology, and fibrosis, providing contract research services with proprietary animal models and histopathology analysis.

Hyderabad-based Indian CRO providing contract research in discovery chemistry, biology, DMPK, and clinical development with integrated data analytics platform GOSTAR.

Preclinical CRO specializing in CNS drug discovery using proprietary AI-powered behavioral phenotyping platforms for neurological and psychiatric disorders.

Preclinical neuroscience CRO spun out of GlaxoSmithKline in 2010, specializing in in vivo CNS pharmacology models for psychedelic compound and neurodegeneration research.

European preclinical CRO in Dijon, France, specializing in oncology, inflammation, and infectious disease drug discovery including targeted radiotherapy programs.

UK nonclinical safety CRO founded by former AstraZeneca scientists, specializing in integrated toxicology and ion channel electrophysiology studies for regulatory drug safety assessment.

Barcelona-based preclinical CRO pioneering zebrafish-based platforms for efficacy testing, safety pharmacology, and toxicity assessment of pharmaceutical and chemical compounds.

Dr. Reddy's wholly-owned integrated CRO and CDMO for small molecules and biologics, combining 650+ Indian scientists with GMP manufacturing in the UK, Mexico, and India.

Global preclinical and drug discovery CRO offering the world's largest catalog of human fresh tissue assays for efficacy, ADME, and safety testing in GLP-accredited labs across the US, UK, and Japan.

Boulder-based biologic discovery CRO integrating antibody discovery, protein engineering, function-first screening, and early developability assessment for complex biotherapeutics.

GLP-compliant preclinical CRO in Austin, Texas, offering 100+ validated xenograft efficacy models, IND-enabling toxicology, and RNAi therapeutic development services.

Precision oncology CRO using patient-derived orthotopic xenograft models and predictive AI to guide drug selection and oncology development decisions.

New Jersey-based bioanalytical and ADME/DMPK CRO founded in 1987, providing clinical and nonclinical metabolism and pharmacokinetics services to pharma, biotech, and agrochemical industries.

Specialty preclinical CRO focused on non-GLP ophthalmic and oncology efficacy studies, providing in vivo animal model services for ocular disease and solid tumor drug development.

Specialty CRO focused on translational oncology services. Champions provides patient-derived xenograft (PDX) tumor models, ex vivo tumor platforms, and oncology pharmacology studies.